Search

Displaying results 4951 - 4960 of 9693 in total
  1. Drug

    Casimiroin

    go.drugbank.com/drugs/DB08744
    Experimental

    Casimiroin is a quinone reductase 2 inhibitor isolated from _Casimiroa edulis_.

  2. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

  3. Drug

    Pipazethate

    go.drugbank.com/drugs/DB08796
    Investigational

    A non-narcotic oral antitussive agent.

  4. Drug

    Salicylamide

    go.drugbank.com/drugs/DB08797
    Approved

    Salicylamide is a non-prescription drug with analgesic and antipyretic properties. It has similar medicinal uses to aspirin.

  5. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    Metiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.

  7. Drug

    Bopindolol

    go.drugbank.com/drugs/DB08807
    Experimental

    Bopindolol (INN) is an ester prodrug for the beta blocker pindolol.

  8. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness.

  9. Drug

    Cinitapride

    go.drugbank.com/drugs/DB08810
    Investigational

    Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.

  10. Drug

    Lurasidone

    go.drugbank.com/drugs/DB08815
    ApprovedInvestigational

    Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...